Corbus Pharmaceuticals will host an in-person and virtual event at ASCO 2026 to present updated Phase 1/2 data on CRB-701, a next-gen antibody-drug conjugate for head and neck squamous cell carcinoma (HNSCC). The data includes clinical response durability and patient subgroup analysis from 75 participants. The event features leading oncology experts and follows recent FDA alignment on CRB-701's regulatory path. This presentation highlights Corbus's progress in developing innovative cancer therapies targeting Nectin-4 expressing tumors.
Temenos has been recognized by CNBC as one of the World’s Top Fintech Companies for the third consecutive year, selected from 3,500 global firms. This accolade reflects Temenos' strong performance and innovation in banking technology, particularly in...
During week 30 of 2026 (July 20-24), Sampo Oyj bought back a total of 1,352,794 of its A-shares at a weighted average price of €9.60 per share. This share buyback is part of a program authorized by the company's general meeting on April 22, 2026, wit...
Bitcoin briefly dropped as U.S. spot bitcoin ETFs saw $465 million in outflows over two days, ending a week-long inflow streak. Despite this, Bitcoin held steady between $63,700 and $65,500, supported by rising U.S. liquidity hitting $5.92 trillion, ...
Rokmaster Resources has entered an exclusive option agreement to acquire 100% interest in the Cristal Property, a 9 km² copper exploration site in northern Chile known for promising geophysical anomalies indicating a potential large porphyry copper s...
AstraZeneca reported second-quarter earnings that surpassed analyst expectations, with core earnings per share rising 21% to $2.63, though revenue slightly missed forecasts at $15.4 billion. Growth in oncology and rare diseases offset weaker sales fr...
